Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oral and anal carriage of Neisseria meningitidis among sexually active HIV-infected men who have sex with men in Denmark 2014-15

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Silent Hypoxia in Patients with SARS CoV-2 Infection before Hospital Discharge

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Noninvasive Hemodynamic Evaluation at Rest in Heart Failure with Preserved Ejection Fraction

    Research output: Contribution to journalReviewpeer-review

  2. Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sex differences in congestive markers in patients hospitalized for acute heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Hydroxychloroquine has been proposed as a primary prophylactic agent against COVID-19. We aimed to investigate if patients treated with hydroxychloroquine for a non-SARS-CoV-2-indication had a lower risk of verified infection with SARS-CoV-2, compared with matched controls.

METHODS: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e. both during and before SARS-CoV-2 was confirmed in Denmark) matched by age and sex with controls. Data were collected using the Danish national registries containing complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection.

RESULTS: A total of 5,488 hydroxychloroquine-users were matched with 54,486 non-users. At baseline the groups differed on diagnoses of pulmonary, cardiovascular, renal,gastrointestinal / metabolic disease and dementia as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indication was not associated with any change in confirmed SARS-CoV-2 [HR of 0.90 (95% Confidence Interval 0.76-1.07)] This result was robust in the propensity-score matched sensitivity analysis.

CONCLUSION: Our study, which is the largest to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.

Original languageEnglish
JournalInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN1201-9712
DOIs
Publication statusE-pub ahead of print - 1 Jun 2021

ID: 66135180